-
Je něco špatně v tomto záznamu ?
Imidazo[1,2-c]pyrimidin-5(6H)-one as a novel core of cyclin-dependent kinase 2 inhibitors: Synthesis, activity measurement, docking, and quantum mechanical scoring
H. Ajani, J. Jansa, C. Köprülüoğlu, P. Hobza, V. Kryštof, A. Lyčka, M. Lepsik,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
29687635
DOI
10.1002/jmr.2720
Knihovny.cz E-zdroje
- MeSH
- cyklin-dependentní kinasa 2 antagonisté a inhibitory chemie MeSH
- inhibitory proteinkinas chemická syntéza chemie farmakologie MeSH
- kvantová teorie MeSH
- lidé MeSH
- pyrimidiny chemická syntéza chemie farmakologie MeSH
- racionální návrh léčiv MeSH
- simulace molekulového dockingu MeSH
- vazba proteinů MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
We report on the synthesis, activity testing, docking, and quantum mechanical scoring of novel imidazo[1,2-c]pyrimidin-5(6H)-one scaffold for cyclin-dependent kinase 2 (CDK2) inhibition. A series of 26 compounds substituted with aromatic moieties at position 8 has been tested in in vitro enzyme assays and shown to inhibit CDK2. 2D structure-activity relationships have ascertained that small substituents at position 8 (up to the size of naphtyl or methoxyphenyl) generally lead to single-digit micromolar IC50 values, whereas bigger substituents (substituted biphenyls) decreased the compounds' activities. The binding modes of the compounds obtained using Glide docking have exhibited up to 2 hinge-region hydrogen bonds to CDK2 and differed in the orientation of the inhibitor core and the placement of the 8-substituents. Semiempirical quantum mechanics-based scoring identified probable favourable binding modes, which will serve for future structure-based design and synthetic optimization of substituents of the heterocyclic core. In summary, we have identified a novel core for CDK2 inhibition and will explore it further to increase the potencies of the compounds and also monitor selectivities against other protein kinases.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045476
- 003
- CZ-PrNML
- 005
- 20200115102123.0
- 007
- ta
- 008
- 200109s2018 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/jmr.2720 $2 doi
- 035 __
- $a (PubMed)29687635
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Ajani, Haresh $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague 6, Czech Republic. Regional Centre of Advanced Technologies and Materials, Department of Physical Chemistry, Palacký University, Olomouc, Czech Republic.
- 245 10
- $a Imidazo[1,2-c]pyrimidin-5(6H)-one as a novel core of cyclin-dependent kinase 2 inhibitors: Synthesis, activity measurement, docking, and quantum mechanical scoring / $c H. Ajani, J. Jansa, C. Köprülüoğlu, P. Hobza, V. Kryštof, A. Lyčka, M. Lepsik,
- 520 9_
- $a We report on the synthesis, activity testing, docking, and quantum mechanical scoring of novel imidazo[1,2-c]pyrimidin-5(6H)-one scaffold for cyclin-dependent kinase 2 (CDK2) inhibition. A series of 26 compounds substituted with aromatic moieties at position 8 has been tested in in vitro enzyme assays and shown to inhibit CDK2. 2D structure-activity relationships have ascertained that small substituents at position 8 (up to the size of naphtyl or methoxyphenyl) generally lead to single-digit micromolar IC50 values, whereas bigger substituents (substituted biphenyls) decreased the compounds' activities. The binding modes of the compounds obtained using Glide docking have exhibited up to 2 hinge-region hydrogen bonds to CDK2 and differed in the orientation of the inhibitor core and the placement of the 8-substituents. Semiempirical quantum mechanics-based scoring identified probable favourable binding modes, which will serve for future structure-based design and synthetic optimization of substituents of the heterocyclic core. In summary, we have identified a novel core for CDK2 inhibition and will explore it further to increase the potencies of the compounds and also monitor selectivities against other protein kinases.
- 650 _2
- $a cyklin-dependentní kinasa 2 $x antagonisté a inhibitory $x chemie $7 D051357
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a vazba proteinů $7 D011485
- 650 _2
- $a inhibitory proteinkinas $x chemická syntéza $x chemie $x farmakologie $7 D047428
- 650 _2
- $a pyrimidiny $x chemická syntéza $x chemie $x farmakologie $7 D011743
- 650 _2
- $a kvantová teorie $7 D011789
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jansa, Josef $u Research Institute for Organic Syntheses (VUOS), Pardubice-Rybitví, Czech Republic. Department of Organic Chemistry, Faculty of Science, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Köprülüoğlu, Cemal $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague 6, Czech Republic. Regional Centre of Advanced Technologies and Materials, Department of Physical Chemistry, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Hobza, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague 6, Czech Republic. Regional Centre of Advanced Technologies and Materials, Department of Physical Chemistry, Palacký University, Olomouc, Czech Republic.
- 700 1_
- $a Kryštof, Vladimír $u Laboratory of Growth Regulators, Centre of the Region Haná for Biotechnological and Agricultural Research, Faculty of Science, Palacký University and Institute of Experimental Botany, Olomouc, Czech Republic.
- 700 1_
- $a Lyčka, Antonín $u Research Institute for Organic Syntheses (VUOS), Pardubice-Rybitví, Czech Republic. Faculty of Science, University of Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Lepsik, Martin
- 773 0_
- $w MED00002813 $t Journal of molecular recognition : JMR $x 1099-1352 $g Roč. 31, č. 9 (2018), s. e2720
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29687635 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200115102456 $b ABA008
- 999 __
- $a ok $b bmc $g 1483744 $s 1084149
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 31 $c 9 $d e2720 $e 20180423 $i 1099-1352 $m JMR. Journal of molecular recognition $n J Mol Recognit $x MED00002813
- LZP __
- $a Pubmed-20200109